Papers
9
Total Citations
164
H-Index
7
About
Andrea Necchi is a leading urologic oncologist whose research focuses on optimizing surgical and perioperative management for bladder, kidney, and penile cancers. Her most impactful work stems from the PURE-01 trial, which prospectively assessed the safety of radical cystectomy following neoadjuvant pembrolizumab in bladder cancer patients—a study that has garnered 69 citations and helped reshape perioperative immunotherapy protocols. Dr. Necchi has also made significant contributions to comparative effectiveness research, including a large propensity-score matched analysis of open versus robotic cystectomy involving nearly 10,000 patients, demonstrating her commitment to evidence-based surgical decision-making. Her work extends to penile cancer, where she has conducted systematic reviews and meta-analyses on minimally invasive inguinal lymph node dissection, advancing surgical staging techniques. Additionally, she has developed risk calculators for nephron-sparing surgery in kidney cancer and explored temporal trends in urinary diversion after cystectomy. With multiple publications challenging conventional paradigms—such as neoadjuvant chemotherapy versus immunotherapy for muscle-invasive bladder cancer—Dr. Necchi’s research consistently bridges surgical innovation and oncologic outcomes, making her a pivotal figure in modern urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9